^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lymphoma

    Related cancers:
    10h
    Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies (clinicaltrials.gov)
    P2, N=20, Completed, University of Washington | Active, not recruiting --> Completed | Trial completion date: Aug 2029 --> Jan 2026
    Trial completion • Trial completion date
    |
    Opdivo (nivolumab)
    16h
    CD70-targeted immunoPET Imaging of Malignant Cancers (clinicaltrials.gov)
    P2, N=300, Recruiting, RenJi Hospital | Phase classification: P=N/A --> P2
    Phase classification
    |
    CD70 (CD70 Molecule)
    17h
    G-COR: Global Cardio Oncology Registry (clinicaltrials.gov)
    P=N/A, N=5000, Recruiting, The Cleveland Clinic | Trial completion date: Jul 2027 --> Jul 2029 | Trial primary completion date: Jul 2025 --> Jul 2029
    Trial completion date • Trial primary completion date
    17h
    CCTG LY18-A: Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, Canadian Cancer Trials Group | Recruiting --> Active, not recruiting | N=18 --> 40
    Enrollment closed • Enrollment change
    |
    Venclexta (venetoclax) • cisplatin • gemcitabine • dexamethasone • Rituxan Hycela (rituximab/hyaluronidase) • Monjuvi (tafasitamab-cxix) • Columvi (glofitamab-gxbm)
    17h
    Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia (clinicaltrials.gov)
    P2, N=99, Active, not recruiting, Christian Buske | Trial completion date: Aug 2028 --> May 2028 | Trial primary completion date: Aug 2028 --> May 2028
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    CD20 positive
    |
    Imbruvica (ibrutinib) • carfilzomib
    19h
    SIGMA: A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P3, N=49, Recruiting, Grifols Biologicals, LLC
    New P3 trial
    20h
    Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, City of Hope Medical Center
    New P2 trial
    |
    clonoSEQ
    |
    Venclexta (venetoclax) • Calquence (acalabrutinib) • Monjuvi (tafasitamab-cxix)
    22h
    Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy (clinicaltrials.gov)
    P3, N=550, Recruiting, Kite, A Gilead Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV
    1d
    T-cell fitness, metabolic tumor volume, and serum LDH levels are associated with response to axicabtagene ciloleucel. (PubMed, Int J Hematol)
    Axi-cel demonstrated substantial efficacy in Japanese patients with r/r LBCL. The 2L setting was associated with higher toxicity and numerically higher PFS.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    LDH elevation
    |
    Yescarta (axicabtagene ciloleucel)
    1d
    Anti-CD3/CD20 bispecific antibodies as salvage therapy after CAR-T failure in relapsed/refractory large B-cell lymphoma: a systematic review and meta-analysis. (PubMed, Ann Hematol)
    Among the agents studied, epcoritamab demonstrated the highest ORR...Cytokine release syndrome was the most common toxicity, predominantly grade 1-2, while neurotoxicity and hematologic adverse events were manageable. In conclusion, CD3×CD20 BsAbs exhibit meaningful efficacy and acceptable safety profiles in R/R LBCL patients following CAR-T failure, particularly in those with longer relapse intervals.
    Retrospective data • Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Epkinly (epcoritamab-bysp)
    1d
    Decoding IGLL5 Mutation-Mediated BCR Signaling: A Novel Mechanism of CD8+ T Cell Exhaustion and Ocular MALT Lymphoma Progression. (PubMed, Adv Sci (Weinh))
    Pharmacologic inhibition further shows that combined BTK inhibitor and rituximab treatment suppresses IGLL5-associated BCR activation. Together, these findings support a mutation-associated mechanism in a subset of OAML and nominate IGLL5-related signaling as a potential therapeutic vulnerability.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD79B (CD79b Molecule) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • CD79A (CD79a Molecule) • IGLL5 (Immunoglobulin Lambda Like Polypeptide 5)
    |
    Rituxan (rituximab)
    1d
    Clinical utility of tumour markers in skeletal metastasis of unknown primary at the initial visit. (PubMed, Jpn J Clin Oncol)
    Serum tumour markers can assist early diagnostic stratification at the initial presentation of skeletal metastasis before primary-site identification. A selective testing strategy focusing on sIL-2R, IEP, CEA, and CK19, with PSA added in men and Tg when clinically indicated, may improve diagnostic efficiency and provide a basis for considering a bone-metastasis-oriented diagnostic approach.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • IL2 (Interleukin 2) • KRT19 (Keratin 19)